Efficacy and safety of linagliptin/metformin fixed-dose combination as initial therapy in drug-naive Asian patients with type 2 diabetes

被引：0
|
作者：
Gong, Y. [1 ]
Mu, Y. [2 ]
Fan, B. [3 ]
Hehnke, U. [1 ]
Pan, C. [2 ]
机构：
[1] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[2] Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China
[3] Boehringer Ingelheim China Investment Co Ltd, Shanghai, Peoples R China
来源：
DIABETOLOGIA | 2015年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
807
引用
收藏
页码：S388 / S388
页数：1
相关论文
共 50 条
  • [1] Efficacy and Safety of Linagliptin/Metformin Fixed-Dose Combination (FDC) as Initial Therapy in Drug-Naive Asian Patients with Type 2 Diabetes (T2D)
    Pan, Changyu
    Mu, Yiming
    Fan, Bei
    Hehnke, Uwe
    Gong, Yan
    [J]. DIABETES, 2015, 64 : A323 - A323
  • [2] Efficacy and safety of linagliptin/metformin single-pill combination as initial therapy in drug-naive Asian patients with type 2 diabetes
    Mu, Yiming
    Pan, Changyu
    Fan, Bei
    Hehnke, Uwe
    Zhang, Xiuzhen
    Zhang, Xuejun
    Wang, Xiaoyue
    Liu, Jingdong
    Zhang, Ying
    Du, Jianling
    Ma, Jianhua
    Gong, Yan
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2017, 124 : 48 - 56
  • [3] Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin versus pioglitazone in drug-naive patients with type 2 diabetes
    Perez-Monteverde, A.
    Seck, T.
    Xu, L.
    Liu, G.
    Lee, M. A.
    Sisk, C. McCrary
    Williams-Herman, D. E.
    Kaufman, K. D.
    Goldstein, B. J.
    [J]. DIABETOLOGIA, 2010, 53
  • [4] Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naive patients with type 2 diabetes
    Perez-Monteverde, A.
    Seck, T.
    Xu, L.
    Lee, M. A.
    Sisk, C. M.
    Williams-Herman, D. E.
    Engel, S. S.
    Kaufman, K. D.
    Goldstein, B. J.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2011, 65 (09) : 930 - 938
  • [5] Efficacy and Safety of Linagliptin/Metformin Fixed-Dose Combination (FDC) as Initial Therapy in Asian Patients with Type 2 Diabetes (T2D) and Severe Hyperglycemia
    Mu, Yiming
    Pan, Changyu
    Fan, Bei
    Hehnke, Uwe
    Gong, Yan
    [J]. DIABETES, 2015, 64 : A315 - A315
  • [6] Efficacy and safety of gemigliptin/metformin initial combination therapy versus either as monotherapy in drug-naive patients with type 2 diabetes
    Lim, S.
    Min, K.
    Yu, J. -M.
    Chamnan, P.
    Kim, E.
    Yoon, K. -H.
    Kwon, S.
    Moon, M.
    Lee, K.
    Kim, D. -J.
    Kim, M.
    Wongtanate, M.
    Kim, E.
    Kim, S. -H.
    Lee, M. -K.
    [J]. DIABETOLOGIA, 2015, 58 : S54 - S54
  • [7] Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes
    Lingvay, Ildiko
    Beetz, Nadine
    Sennewald, Regina
    Schuler-Metz, Annette
    Bertulis, Julia
    Loley, Christina
    Lang, Benjamin
    Lippert, Caroline
    Lee, Jisoo
    Manning, Linda Shapiro
    Terada, Derek
    [J]. POSTGRADUATE MEDICINE, 2020, 132 (04) : 337 - 345
  • [8] Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Lobeglitazone in Drug-Naive Patients with Type 2 Diabetes
    Kim, Kyoung Min
    Lee, Seo Young
    Lee, Ji Hyun
    Lee, Dong Hwa
    Oh, Tae Jung
    Jang, Hak Chul
    Lim, Soo
    [J]. DIABETES, 2017, 66 : A346 - A346
  • [9] Efficacy and safety of fixed-dose combination therapy, alogliptin plus metformin, in Asian patients with type 2 diabetes: A phase 3 trial
    Ji, Linong
    Li, Ling
    Kuang, Jian
    Yang, Tao
    Kim, Dong-Jun
    Kadir, Azidah A.
    Huang, Chien-Ning
    Lee, Douglas
    [J]. DIABETES OBESITY & METABOLISM, 2017, 19 (05): : 754 - 758
  • [10] Effects of Rosiglitazone/Metformin Fixed-Dose Combination Therapy and Metformin Monotherapy on Serum Vaspin, Adiponectin and IL-6 Levels in Drug-Naive Patients with Type 2 Diabetes
    Kadoglou, N. P. E.
    Kapelouzou, A.
    Tsanikidis, H.
    Vitta, I.
    Liapis, C. D.
    Sailer, N.
    [J]. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2011, 119 (02) : 63 - 68
12345